Established therapeutic strategies, including RAAS blockers, sodium-glucose cotransporter-2 (SGLT2) inhibitors, Glucagon-like Peptide-1 receptor agonists (GLP-1 RA), non-steroidal mineralocorticoid antagonists (ns-MRAs), and their impact on CKD progression are highlighted. Here, GLP1R is linked to chronic kidney disease.